Contrary to what a lot of people would have expected, Shares of Gilead Sciences, Inc. (NASDAQ:GILD) remain unmoved by the great criticism sweeping through from all sides.
The whole controversy is making a dark cloud of doubt hover over the heads of a lot of people. Many of them are lost and do not know whether to subscribe to the drug or not. However, there is an organization that can shed light on the whole matter and it just did that in good time.
It is the Stat News which has come out to report the findings by the U.S. Food and Drug Administration which happens to be a trusted research body. To help the average citizen with decision making, Stat News also reported about the move made by Safe Medicine Practices which embarked in reviewing the forwarded report.
The report showed that Hepatitis C had caused about 524 persons to suffer from liver failure. The report also showed that another 1,058 were struggling with liver injury. As a matter of fact the report did not look quite attractive and most of the people have been dying with thirst to get Gilead’s response since the delivery of the report. It is this matter that forced Benzinga to find Gilead to find out what the response to the matter would be like.
The company did not hesitate to comment .It was quick to showcase how much it valued patient safety. In a quick defense, Gilead Responded ruled off the claims by the University of Minnesota as invalid. The company exuded great confidence in its endeavor of manufacturing and selling medicines for HCV.
Gilead is not succumbing to any pressure yet and believes he bears the sole right in the United States for commercializing Sovaldi. In as much as criticism is hitting this company really hard, one cannot help but notice the number of lives the drug is saving. A lot of people have sought and believe in it. However, we just have to wait and see the turn of events in the time to come.